CavoGene’s Competitive Advantage
- Gene expression platform for multiple CNS and neurodegenerative diseases
- Validated animal data lead to long term diversified risk
- Transition from research to IND-enabling studies for rapid commercialization
- Emphasis on protecting intellectual property and shareholder value
- Significant potential for non-dilutive financing and partnering activities
- Strategic financing, exit and liquidity options Multiple strategic partnerships
- Exclusive license from UCSD
- 2 issued patents with extensive claims & FTO
- Non-Provisional PCT (2020 actionable date)
- Gavrilovich, Dodd & Lindsey LLP (IP counsel)
- Tucker Ellis, LLP (Corporate counsel)